The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
In concluding statements, Hamid reflected on tremendous progress from an era when advanced skin cancers were untreatable compared to the current landscape of effective immunotherapies and coordinated multidisciplinary care. He stressed ensuring patients understand available therapies and the ability to positively impact their disease. Pisano emphasized reclassifying basal cell and squamous cell carcinomas as serious vs indolent malignancies warranting immunotherapy when appropriate. She highlighted setting patient expectations and fully leveraging specialist expertise via integrated care teams. Barker advocated conducting pivotal trials through cooperative groups to refine care pathways, enable treatment de-escalation when feasible, and disseminate emerging strategies into community settings. Patel described the transformation of skin cancer conferences into multidisciplinary forums where cross-pollination of specialty knowledge ultimately optimizes patient-centered decision-making.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More